HealthCap

Ferrokin Biosciences Inc. develops and markets medical devices. The company offers iron chelator for the treatment of iron-overload in patients with transfusion-dependent hereditary and acquired refractory anemias. The company is based in San Carlos, California.

Biolipox is a research-intense pharmaceutical company that develops treatments for inflammatory diseases. This includes widespread diseases such as asthma, COPD, rhinitis, and inflammatory and rheumatic pain. The company offers its users with current arachidonic acid research. Arachidonic acid is an endogenous substance that plays a central role in the development of inflammatory diseases. It is an established research area that empowers several drugs such as Aspirin, Naproxen, and Singulair. Biolipox is a Sweden-based company that was founded in 2000 and the company was acquired by Orexo on November 23, 2007.

Direct Conversion provides detectors into imaging systems that are used across the globe

HelloBetter offers online psychological training programs. The company offers training programs in areas, such as stress, depression, anxiety and panic, and sleep disorders. Its training programs help to reduce stress, depression, fear and panic, mood in diabetes, drink less alcohol, and brooding and worries. HelloBetter was formerly known as GET.ON Institut für Online-Gesundheitstrainings GmbH and changed its name to HelloBetter in January 2020. The company was founded in 2015 and is headquartered in Hamburg, Germany with an additional office in Berlin, Germany.

Direct Conversion provides detectors into imaging systems that are used across the globe

PTC Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of orally administered and small-molecule drugs. It offers Ataluren, an orally administered small-molecule investigational new drug for the treatment of cystic fibrosis and duchenne muscular dystrophy caused by nonsense mutations. The company also provides PTC299, an anti-angiogenesis drug for the treatment of metastatic breast cancer, multiple tumors, and neurofibromatosis. Its products are used for the treatment of genetic disorders, oncology, and infectious diseases. PTC Therapeutics, Inc. was founded in 1998 and is based in South Plainfield, New Jersey.

- Jerini was founded in 1994 as a spin-off from the Medical Faculty (Charité) Humboldt University Berlin to commercialize the SPOT™ technology. The evolving SPOT™ platform was marketed as fee for service projects to pharmaceutical and biotech companies (1995 to 1999). The revenues generated supported the expansion of the company and its technology development. At this stage no venture capital was raised. Due to the expanding applications of its technology platform in drug discovery and proteomics Jerini began its transformation into a drug discovery company. - To support and accelerate the drug discovery transition Jerini raised Euro 4.6 million in January 2000 in a first financing round that included local investors IBB-Bet. GmbH, bmp AG and tbg. In 2001 the company converted to an AG (joint-stock company) and closed its second, private financing round raising Euro 20 million in November 2001. The investors in this round included an international group represented by TVM, 3i, Polytechnos and Sanders Morris and Harris. - In 2000 Jerini started creating the medicinal chemistry platform PepMed™ focusing on the identification of peptide lead structures addressing difficult protein targets and their subsequent systematic transformation into drug-like molecules. - In December 2001 Jerini started its first clinical trials with Icatibant, a peptidomimetic bradykinin receptor antagonist for the indication defined as end-stage liver cirrhosis.

Lumavita AG, a biopharmaceutical company, engages in the development and commercialization of novel anti-infectives for women's health. Its products include FemiFect, an antibiotic to treat infections known to cause vaginitis, such as bacteria, fungi, and protozoa; and SPK-601 that is for the treatment of human papilloma virus (HPV) and herpes simplex virus (HSV). The company markets its products through distributors. Lumavita AG was formerly known as Shogoo Pharmaceuticals, AG and changed its name to Lumavita AG in December, 2007. The company was founded in 2008 and is based in Basel, Switzerland. Lumavita AG operates as a subsidiary of Shogoo Pharmaceuticals KK.

Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its lead product candidate is FPI-1434 that is in Phase 1 clinical trials as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company is also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it is progressing its earlier-stage product candidate, FPI-1966 into clinical development for the treatment of head and neck, and bladder cancers expressing fibroblast growth factor receptor. The company was founded in 2014 and is headquartered in Hamilton, Canada.

ABIONYX Pharma SA, a biopharmaceutical company, discovers and develops high density lipoprotein (HDL) therapies for the treatment of cardiovascular and metabolic diseases. The company is developing a portfolio of HDL therapies, which include HDL mimetics for the rapid regression of atherosclerotic plaque in high-risk patients. It is developing CER-001, an engineered complex of recombinant human apoA-I, the structural protein of HDL, and phospholipids that is in Phase II clinical trials designed to mimicks the structural and functional biological properties of pre-beta HDL for the treatment of post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients; and CER-209, a drug candidate that is in Phase I clinical trial for the treatment of metabolic diseases in the liver, as well as atherosclerois and non-alcoholic steato-hepatitis. The company was formerly known as Cerenis Therapeutics Holding SA and changed its name to ABIONYX Pharma SA in August 2019. ABIONYX Pharma SA was founded in 2005 and is based in Labege, France.

Spruce Biosciences is a clinical-stage biopharmaceutical focused on developing new treatments for rare endocrine disorders. The company is driven by its mission is to develop meaningful therapies for patients with rare diseases affecting the hypothalamic-pituitary-adrenal. They are committed to transforming the quality of life for patients who have been underserved by scientific innovation.

Oncorena AB develops drugs for cancer. It offers Oncorena that provides pharmacological treatment for metastasing clear cell renal cancer. The company is based in Göteborg, Sweden.

Biolipox is a research-intense pharmaceutical company that develops treatments for inflammatory diseases. This includes widespread diseases such as asthma, COPD, rhinitis, and inflammatory and rheumatic pain. The company offers its users with current arachidonic acid research. Arachidonic acid is an endogenous substance that plays a central role in the development of inflammatory diseases. It is an established research area that empowers several drugs such as Aspirin, Naproxen, and Singulair. Biolipox is a Sweden-based company that was founded in 2000 and the company was acquired by Orexo on November 23, 2007.

- Jerini was founded in 1994 as a spin-off from the Medical Faculty (Charité) Humboldt University Berlin to commercialize the SPOT™ technology. The evolving SPOT™ platform was marketed as fee for service projects to pharmaceutical and biotech companies (1995 to 1999). The revenues generated supported the expansion of the company and its technology development. At this stage no venture capital was raised. Due to the expanding applications of its technology platform in drug discovery and proteomics Jerini began its transformation into a drug discovery company. - To support and accelerate the drug discovery transition Jerini raised Euro 4.6 million in January 2000 in a first financing round that included local investors IBB-Bet. GmbH, bmp AG and tbg. In 2001 the company converted to an AG (joint-stock company) and closed its second, private financing round raising Euro 20 million in November 2001. The investors in this round included an international group represented by TVM, 3i, Polytechnos and Sanders Morris and Harris. - In 2000 Jerini started creating the medicinal chemistry platform PepMed™ focusing on the identification of peptide lead structures addressing difficult protein targets and their subsequent systematic transformation into drug-like molecules. - In December 2001 Jerini started its first clinical trials with Icatibant, a peptidomimetic bradykinin receptor antagonist for the indication defined as end-stage liver cirrhosis.

Camel-IDS develops radiopharmaceuticals for cancer patients. Its product, CAM-H2, treats HER2 positive cancers. It also engages in clinical development to treat breast cancer patients; and develops compounds for other cancer indications. The company was incorporated in 2014 and is based in Brussels, Belgium.

Hemab is focused on the development of bispecific antibodies for the treatment of rare bleeding disorders.

Elsa is a platform for patient driven research for better drugs, health and prevention. Elsa lets patients become their own personal researchers by providing them with a better understanding around how lifestyle factors may affect their disease activity measurements for chronic disease. To support them from a scientific perspective, Elsa gives them access to data on their specific disease (initially we work with rheumatoid arthritis) through the Riskminder foundation and scientific studies at Karolinska Institutet.

Camel-IDS develops radiopharmaceuticals for cancer patients. Its product, CAM-H2, treats HER2 positive cancers. It also engages in clinical development to treat breast cancer patients; and develops compounds for other cancer indications. The company was incorporated in 2014 and is based in Brussels, Belgium.

CARISMA Therapeutics Inc., a biotechnology company, develops CAR macrophages, an approach to immunotherapy. CARISMA Therapeutics Inc. was formerly known as CARMA Therapeutics Inc. and changed its name to CARISMA Therapeutics Inc. in June 2018. The company was incorporated in 2016 and is headquartered in Philadelphia, Pennsylvania.

Rainier Therapeutics, Inc., a biotechnology company, develops a targeted biologic for the potential treatment of early stage and metastatic bladder cancer. It offers Vofatamab (B-701), a human monoclonal antibody that targets and specifically blocks the activity of FGFR3 (fibroblast growth factor receptor 3) that is used for the treatment for metastatic bladder cancer. Rainier Therapeutics, Inc. was formerly known as BioClin Therapeutics, Inc. and changed its name to Rainier Therapeutics, Inc. in November 2018. The company was founded in 2010 and is based in San Leandro, California.

Oncorena AB develops drugs for cancer. It offers Oncorena that provides pharmacological treatment for metastasing clear cell renal cancer. The company is based in Göteborg, Sweden.

HelloBetter offers online psychological training programs. The company offers training programs in areas, such as stress, depression, anxiety and panic, and sleep disorders. Its training programs help to reduce stress, depression, fear and panic, mood in diabetes, drink less alcohol, and brooding and worries. HelloBetter was formerly known as GET.ON Institut für Online-Gesundheitstrainings GmbH and changed its name to HelloBetter in January 2020. The company was founded in 2015 and is headquartered in Hamburg, Germany with an additional office in Berlin, Germany.

Direct Conversion provides detectors into imaging systems that are used across the globe

HelloBetter offers online psychological training programs. The company offers training programs in areas, such as stress, depression, anxiety and panic, and sleep disorders. Its training programs help to reduce stress, depression, fear and panic, mood in diabetes, drink less alcohol, and brooding and worries. HelloBetter was formerly known as GET.ON Institut für Online-Gesundheitstrainings GmbH and changed its name to HelloBetter in January 2020. The company was founded in 2015 and is headquartered in Hamburg, Germany with an additional office in Berlin, Germany.

ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.

ABIONYX Pharma SA, a biopharmaceutical company, discovers and develops high density lipoprotein (HDL) therapies for the treatment of cardiovascular and metabolic diseases. The company is developing a portfolio of HDL therapies, which include HDL mimetics for the rapid regression of atherosclerotic plaque in high-risk patients. It is developing CER-001, an engineered complex of recombinant human apoA-I, the structural protein of HDL, and phospholipids that is in Phase II clinical trials designed to mimicks the structural and functional biological properties of pre-beta HDL for the treatment of post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients; and CER-209, a drug candidate that is in Phase I clinical trial for the treatment of metabolic diseases in the liver, as well as atherosclerois and non-alcoholic steato-hepatitis. The company was formerly known as Cerenis Therapeutics Holding SA and changed its name to ABIONYX Pharma SA in August 2019. ABIONYX Pharma SA was founded in 2005 and is based in Labege, France.

ABIONYX Pharma SA, a biopharmaceutical company, discovers and develops high density lipoprotein (HDL) therapies for the treatment of cardiovascular and metabolic diseases. The company is developing a portfolio of HDL therapies, which include HDL mimetics for the rapid regression of atherosclerotic plaque in high-risk patients. It is developing CER-001, an engineered complex of recombinant human apoA-I, the structural protein of HDL, and phospholipids that is in Phase II clinical trials designed to mimicks the structural and functional biological properties of pre-beta HDL for the treatment of post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients; and CER-209, a drug candidate that is in Phase I clinical trial for the treatment of metabolic diseases in the liver, as well as atherosclerois and non-alcoholic steato-hepatitis. The company was formerly known as Cerenis Therapeutics Holding SA and changed its name to ABIONYX Pharma SA in August 2019. ABIONYX Pharma SA was founded in 2005 and is based in Labege, France.

CARISMA Therapeutics Inc., a biotechnology company, develops CAR macrophages, an approach to immunotherapy. CARISMA Therapeutics Inc. was formerly known as CARMA Therapeutics Inc. and changed its name to CARISMA Therapeutics Inc. in June 2018. The company was incorporated in 2016 and is headquartered in Philadelphia, Pennsylvania.

BONESUPPORT is a medical technology company dedicated to the development of injectable osteoconductive biomaterials for the treatment of fragility fractures caused by osteoporosis, and bone voids or gaps caused by trauma, disease or related to surgical procedures. The company's mission is to restore health to enhance the quality of life for patients with bone disorders. BONESUPPORT was founded on 2000 and is headquartered in Lund, Sweden.

PTC Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of orally administered and small-molecule drugs. It offers Ataluren, an orally administered small-molecule investigational new drug for the treatment of cystic fibrosis and duchenne muscular dystrophy caused by nonsense mutations. The company also provides PTC299, an anti-angiogenesis drug for the treatment of metastatic breast cancer, multiple tumors, and neurofibromatosis. Its products are used for the treatment of genetic disorders, oncology, and infectious diseases. PTC Therapeutics, Inc. was founded in 1998 and is based in South Plainfield, New Jersey.

Aprea AB is a Swedish biotech company focusing on the discovery and development of novel anticancer compounds reactivating the tumor suppressor protein p53. The Company's lead program, APR-246, is a first-in-class small molecule drug candidate in clinical development. Aprea's main shareholder is KDev Investments AB, an investment vehicle owned by Karolinska Development AB (Nasdaq Stockholm: KDEV) and Rosetta Capital Ltd. Other shareholders include Östersjöstiftelsen, Praktikerinvest, and KCIF Co-Investment Fund KB.

Direct Conversion provides detectors into imaging systems that are used across the globe

Renovis, Inc. is a biopharmaceutical company developing drugs to treat neurological diseases and disorders. The Company is currently developing products for acute ischemic stroke, for the treatment of neuropathic pain, and for the treatment of acute post-operative pain.

Tisbury Pharmaceuticals, Inc. discovers, develops, and commercializes therapy to treat primary open angle glaucoma. The company's clinical candidate, R-801, accelerates flow via the trabecular meshwork via redox catalysis and K+-ATP (channel activation). The company was incorporated in 2017 and is based in Beverly, Massachusetts.

BioStratum Incorporated develops therapeutic targets and drug candidates for preventing and treating kidney diseases, cancer, and autoimmune diseases. It offers Pyridorin, a small molecule drug candidate to treat diabetic kidney disease; and Angiocol, an anti-angiogenesis drug candidate that inhibits the growth of tumors in animal models of cancer. The company’s research pipeline includes Nephrin, a molecular target for the treatment of proteinuria; and diabetic nephropathy susceptibility genes. BioStratum Incorporated was founded in 1994 and is headquartered in Durham, North Carolina.

Gyros is the world leader in automated micro-immunoassays for therapeutic protein development. Gyrolab, the company's automated and open platform, is a versatile analytical tool that dramatically reduces the time required to optimize and execute immunoassays. Time for assay optimization is often cut from weeks, to a matter of days. This results in increased efficiency in process development and in clinical evaluation of therapeutic proteins. The ease of assay transfer is unsurpassed in the industry.

Nexstim is a medical device company that specializes in image-guided transcranial magnetic stimulation. The company is committed to improving the quality of life of patients with significant unmet clinical needs. It has developed a SmartFocus TMS technology designed for the treatment of the major depressive disorder. The company was founded in 2000 and is headquartered in Helsinki, Southern Finland.

Aro Biotherapeutics is focused on the development of a new protein drug platform called Centyrins, designed to achieve better efficacy and safety profiles for patients with cancer and other serious diseases. Centyrins are small, non-antibody protein scaffolds that can be expressed as multi-specifics with novel therapeutic mechanisms of action. Centyrins are also ideal for the targeted delivery of complex drug payloads, including nucleic acids.

Tengion, a clinical-stage biotechnology company, is a leader in developing neo-organs and neo-tissues, currently derived from a patient's own (autologous) cells. The Company has completed two Phase 2 human clinical trial in the United States with its Tengion Neo-Bladder Augment for children with neurogenic bladder due to spina bifida and in adults with neurogenic bladder due to spinal cord injury. A successful academic human clinical experience with a urinary Neo-Bladder Augment was reported in The Lancet in April 2006 by investigators from the Children's Hospital Boston. Tengion has an effective investigational new drug application (IND) for its Neo-Urinary Conduit and expects to begin a Phase 1 clinical trial in the first half of 2010 in bladder cancer patients requiring bladder removal.

Doctrin AB operates a healthcare platform for healthcare providers who offer patients digital healthcare services. The platform is a cloud based B2B system for healthcare providers, helping the customers digitalise their patient visits. The company has a technology that replicates how doctors interview their patients. The platform is used for information gathering, decision support, and documentation services. The company was founded in 2016 and is based in Stockholm, Sweden.

InCarda Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops transformative therapies for cardiovascular diseases that enable patients to use in the first moments of acute cardiovascular symptoms. The company develops an inhaled therapy intended to treat paroxysmal atrial fibrillation. InCarda Therapeutics, Inc. was formerly known as Pleiades Cardio-Therapeutics, Inc. and changed its name to InCarda Therapeutics, Inc. in May 2011. The company was founded in 2009 and is based in Newark, California.

Immune Targeting Systems (ITS) Limited is developing synthetic vaccines for mutating viruses. The Company's enabling T-cell vaccine platform enables it to target highly conserved parts of the virus ("antigens") and direct an T-cell immune response to those cells in the body infected with one of these difficult viruses. The fluoropeptide vaccine technology then delivers these antigens into the body and promotes robust T-cell immunity without requiring potentially toxic adjuvants which are normally used with vaccines to boost the responses achieved. The company was founded in late 2003 and is located at the London BioScience Innovation Centre, based in London. In June 2007 the company raised its first major venture capital funding from a syndicate of investors including the Novartis Venture Fund, HealthCap, Truffle Capital & the London Technology Fund. Alongside this investment, the London Development Agency has awarded ITS an Exceptional Development Grant.

Tengion, a clinical-stage biotechnology company, is a leader in developing neo-organs and neo-tissues, currently derived from a patient's own (autologous) cells. The Company has completed two Phase 2 human clinical trial in the United States with its Tengion Neo-Bladder Augment for children with neurogenic bladder due to spina bifida and in adults with neurogenic bladder due to spinal cord injury. A successful academic human clinical experience with a urinary Neo-Bladder Augment was reported in The Lancet in April 2006 by investigators from the Children's Hospital Boston. Tengion has an effective investigational new drug application (IND) for its Neo-Urinary Conduit and expects to begin a Phase 1 clinical trial in the first half of 2010 in bladder cancer patients requiring bladder removal.

Sopherion Therapeutics, LLC is a privately held biopharmaceutical company headquartered in Princeton, New Jersey with offices in Cheshire, Connecticut, Estero, Florida and an operating subsidiary, Sopherion Therapeutics Canada, in Toronto, Canada. Sopherion Therapeutics LLC is a specialty biopharmaceutical company with an exclusive licensing agreement with Zeneus Pharma Ltd., now Cephalon, Inc., for the commercialization of Myocet™ (a liposome-encapsulated doxorubicin-citrate complex) in the United States and Canada. Sopherion’s current business focus is the execution of a Phase III, global, randomized, registration trial for first line therapy of invasive, metastatic breast cancer and the development and commercialization of Sopherion’s lead agent, Myocet™. Myocet is being investigated in an FDA agreed upon registration trial in combination with two other drugs, Herceptin® (Trastuzumab) and Taxol (Paclitaxel) vs. Herceptin® and Taxol alone, the current standard of care for first line HER-2-overexpressing metastatic breast cancer. Myocet™, a liposome-encapsulated doxorubicin with reduced cardiotoxicity, is a nanotechnology product that localizes into tumor vasculature and in contrast to parental doxorubicin avoids homing to the heart. This 363 patient global trial in twelve countries has as of 03/06/09 been fully recruited. Unblinding is anticipated by the summer of 2010 with NDA submission for full approval following within 6 months. Myocet® is already a registered drug in Canada, where Sopherion has commercial rights and in Europe where Cephalon has commercial rights for use in first line metastatic breast cancer in combination with cyclophosphamide.; Their Phase III trial is based on a Phase II trial, supported by Roche, which gave a 96% response rate and two and a half year median progression free survival for patients with metastatic breast cancer.

Alba Therapeutics Corporation is a privately held, clinical-stage biopharmaceutical Company focused on the discovery, development and commercialization of pharmaceutical products to treat autoimmune and inflammatory diseases and is based in Baltimore, Maryland. Genetics, environment, aberrant immune response, and barrier dysfunction are all required for autoimmunity. Alba’s technology is based on modifying disease state epithelial permeability using compounds which impact the regulation of tight junctions in cell barriers throughout the body with potential applications in celiac disease, asthma/COPD and acute lung injury.

Wilson Therapeutics is a biopharmaceutical company, based in Stockholm, Sweden, that develops novel therapies for patients with rare diseases such as Wilson Disease. Wilson Therapeutics’ lead product, Decuprate®, is initially being developed as a new treatment for Wilson Disease and is currently being evaluated in a Phase II clinical study in Wilson Disease patients.

GenSight Biologics develops gene therapy-based treatments for retinal degenerative diseases. GenSight Biologics is a privately owned biopharmaceutical company, dedicated to the development and commercialization of gene therapy-based treatments of retinal degenerative diseases. Based on recent results obtained by the teams of its scientific founders, the company develops innovative approaches to prevent retinal degeneration in selected pathological conditions and to restore vision in patients suffering from very low vision or blindness.

BONESUPPORT is a medical technology company dedicated to the development of injectable osteoconductive biomaterials for the treatment of fragility fractures caused by osteoporosis, and bone voids or gaps caused by trauma, disease or related to surgical procedures. The company's mission is to restore health to enhance the quality of life for patients with bone disorders. BONESUPPORT was founded on 2000 and is headquartered in Lund, Sweden.

ChemoCentryx focuses on discovery, development and commercialization of orally-administered small molecule therapeutics that target chemokine receptors and related chemo-attractant receptors. Their small molecule product candidates is designed to target a specific chemokine or chemo-attractant receptor, thereby blocking the inappropriate immune system cascade underlying a given disease.

Priothera Ltd develops orally applied sphingosine 1 phosphate (S1P) receptor modulators for haematological malignancies. It helps reduce egress of T cell subsets from lymphatic tissue. The company develops mocravimod to improve the curative potential of allogeneic haematopoietic stem cell transplant. Priothera Ltd was incorporated in 2020 and is based in Dublin, Ireland with additional location in Saint Louis, France.

Strongbridge Biopharma’s primary focus has been to build its franchise around rare endocrine disorders, which includes product candidates for the treatment of endogenous Cushing’s syndrome and acromegaly, two rare diseases with a high unmet need for innovative treatment options. Given the well-identified and concentrated prescriber base addressing its target markets, the Company intends to use a small, focused sales force to market its products, if approved, in the United States, European Union and other key global markets. The Company intends to identify and in-license or acquire products or product candidates that would be complementary to its existing rare endocrine franchise or that would form the basis for new rare disease franchises.

Algeta ASA, an oncology company, focused on developing targeted therapies for patients with cancer based on its alpha-pharmaceutical platform. Its lead product includes radium-223 dichloride, which completed Phase III clinical trial to treat castration-resistant prostate cancer with bone metastases. The company is also developing alpha-emitter thorium-227 that is in the preclinical phase linked to tumor-targeting molecules to form targeted thorium conjugates. It has an agreement with Bayer Pharma AG for the development and commercialization of radium-223 worldwide. The company was formerly known as Anticancer Therapeutic Inventions AS and changed its name to Algeta ASA in 2003. Algeta ASA was founded in 1997 and is headquartered in Oslo, Norway.

Vivet Therapeutics is dedicated to developing innovative gene therapy treatments for orphan diseases. Vivet Therapeutics is focused on optimizing gene therapy through a partnership with the Fundacion para la Investigacion Medica Aplicada (FIMA) at the Centro de Investigación Medica Aplicada (CIMA, Universidad de Navarra) to develop new AAV vectors specifically targeting the liver and generating new technologies to optimize gene delivery and long term expression.

Orexo develops improved specialty pharmaceuticals and treatments for new areas of use – at a lower cost, in a shorter period of time and at a lower risk – by combining known substances with patented proprietary technologies.

OxThera AB manufactures products for the treatment of primary and secondary hyperoxaluria with bacteria and enzymes. It offers Oxabact, an orally delivered composition of live bacteria to promote the removal of endogenously produced oxalate for the treatment of primary hyperoxaluria and Oxazyme, a non-systemic orally delivered drug composed of recombinant oxalate decarboxylase for the treatment of dietary hyperoxaluria and prevention of kidney stones. The company was founded in 2005 and is based in Stockholm, Sweden with an additional location in Knoxville, Tennessee.

Hybrigenics Pharma is a bio-pharmaceutical company with a focus on research and development of new targets and therapies against cancer.Hybrigenics Pharma has stopped the development of inecalcitol, a vitamin D receptor agonist.Hybrigenics Pharma's research program investigates the action of enzymes called Deubiquitinating Enzymes (DUBs) in the recycling of onco-proteins and the potential activity of proprietary patented DUB inhibitors against various cancer indications.

BeneChill, Inc., a medical device company, develops non-invasive cooling technologies in the United States and Europe. The company develops non-invasive cooling technologies to improve patient outcomes after acute ischemic events, such as cardiac arrest, stroke, and traumatic brain injury. Its RhinoChill System focuses on reducing patient temperature. The company was founded in 2004 and is headquartered in San Diego, California.

BONESUPPORT is a medical technology company dedicated to the development of injectable osteoconductive biomaterials for the treatment of fragility fractures caused by osteoporosis, and bone voids or gaps caused by trauma, disease or related to surgical procedures. The company's mission is to restore health to enhance the quality of life for patients with bone disorders. BONESUPPORT was founded on 2000 and is headquartered in Lund, Sweden.

InCarda Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops transformative therapies for cardiovascular diseases that enable patients to use in the first moments of acute cardiovascular symptoms. The company develops an inhaled therapy intended to treat paroxysmal atrial fibrillation. InCarda Therapeutics, Inc. was formerly known as Pleiades Cardio-Therapeutics, Inc. and changed its name to InCarda Therapeutics, Inc. in May 2011. The company was founded in 2009 and is based in Newark, California.

Doctrin AB operates a healthcare platform for healthcare providers who offer patients digital healthcare services. The platform is a cloud based B2B system for healthcare providers, helping the customers digitalise their patient visits. The company has a technology that replicates how doctors interview their patients. The platform is used for information gathering, decision support, and documentation services. The company was founded in 2016 and is based in Stockholm, Sweden.

Bionaut Pharmaceuticals is a biotechnology company that discovers and advances small molecule drug candidates. The company’s Sentinel Pathway Reporter System has product driven applications, such as initiation and development of drug discovery programs, identifying biomarkers for clinical trials, validating existing drug candidates for a specific disease pathway, and identifying new indications for existing drug candidates and known drugs; and research-driven applications, including deciphering pathways and their relationships, and identifying genes. Bionaut Pharmaceuticals was founded in 2000 and is based in Cambridge, Massachusetts.

Ultragenyx Pharmaceutical develops therapeutics for rare diseases, sometimes referred to as Orphan products. Ultragenyx is a efficient and effective development strategies are essential for success in the rare disease space, in which information may be incomplete or ambiguous, and few development precedents exist. The management team's experience in selecting and developing products with clear mechanisms of action for untreated rare diseases will help Ultragenyx create life-changing therapeutics by leveraging existing yet undeveloped science for these little-known indications.

Altimmune is an emerging biotechnology company located in Montgomery County, MD. Altimmune develops vaccines and other biological products to address unmet market and public health needs. The company uses a proprietary technology for non-invasive intranasal delivery, and has shown proof of principle in animals and in initial human clinical studies. Vaxin Inc., formerly known as Vaxin Pharmaceuticals and ImmuneFocus Corporation, was founded in 1997 by Emerging Technology Partners. Early experiments revealed that DNA incorporated into an adenovirus can elicit an immune response when placed on the surface of the skin, and subsequently research was expanded to include applications on the skin in the nose as well as experimentation with other vectors.

OraPharma is a specialty pharmaceutical company that develops and commercializes products that help improve and maintain oral health. They are dedicated to delivering scientifically and technologically advanced products to dental professionals and their practices. ARESTIN® (minocycline HCl) Microspheres, 1 mg is a locally administered antibiotic (LAA) offering a patented microsphere technology. OraPharma is proud to have introduced this revolutionary approach to treating periodontitis as an adjunct to scaling and root planing and continues to take a leadership role in educating clinicians and consumers on the disease. Read more about ARESTIN® or click here for Prescribing Information.

Oncos Therapeutics develops new cancer therapies based on its next generation oncolytic viruses. The company's unique Advanced Therapy Access Program was started in 2007 for cancer patients in whom standard-of-care therapies have failed. Today, 200 patients have undergone individually tailored oncolytic virus therapy suggesting strong safety and efficacy. The program is based on extensive scientific research at the University of Helsinki and serves as the foundation for ongoing clinical development.

CoreValve is a private company founded in 2001 by Jacques Seguin, M.D., Ph.D., a cardiac surgeon. The vision of the Company was to develop a technology that permits the replacement of failing aortic heart valves without surgical access. Developing the concept of a catheter-based aortic valve replacement procedure, the Company has rapidly advanced this technology from vision to reality. Today, more than 200 patients have experienced successful aortic valve replacement with the CoreValve ReValving™ procedure. CoreValve’s objective is to be the technological, clinical, and market leader in percutaneous heart valve replacement therapies. Current efforts are focused on percutaneous aortic valve replacement, but future efforts will relate to other minimally invasive structural heart disease treatments. CoreValve’s headquarters’ are in Irvine, California, an area renowned for the development of innovative heart valve technologies.

BONESUPPORT is a medical technology company dedicated to the development of injectable osteoconductive biomaterials for the treatment of fragility fractures caused by osteoporosis, and bone voids or gaps caused by trauma, disease or related to surgical procedures. The company's mission is to restore health to enhance the quality of life for patients with bone disorders. BONESUPPORT was founded on 2000 and is headquartered in Lund, Sweden.

IDEA AG develops and commercializes non-invasive targeted therapeutics applied through the skin for delivery of drugs. The company uses Transfer some carriers for transporting the established molecular weight drugs selectively into the skin. It focuses on dermatological and pain therapeutics. The company’s Diractin is a ketoprofen in the Transfersome gel for the treatment of peripheral pain. IDEA AG was founded in 1993 and is based in Munich, Germany.

Rainier Therapeutics, Inc., a biotechnology company, develops a targeted biologic for the potential treatment of early stage and metastatic bladder cancer. It offers Vofatamab (B-701), a human monoclonal antibody that targets and specifically blocks the activity of FGFR3 (fibroblast growth factor receptor 3) that is used for the treatment for metastatic bladder cancer. Rainier Therapeutics, Inc. was formerly known as BioClin Therapeutics, Inc. and changed its name to Rainier Therapeutics, Inc. in November 2018. The company was founded in 2010 and is based in San Leandro, California.

Rainier Therapeutics, Inc., a biotechnology company, develops a targeted biologic for the potential treatment of early stage and metastatic bladder cancer. It offers Vofatamab (B-701), a human monoclonal antibody that targets and specifically blocks the activity of FGFR3 (fibroblast growth factor receptor 3) that is used for the treatment for metastatic bladder cancer. Rainier Therapeutics, Inc. was formerly known as BioClin Therapeutics, Inc. and changed its name to Rainier Therapeutics, Inc. in November 2018. The company was founded in 2010 and is based in San Leandro, California.

Immune Targeting Systems (ITS) Limited is developing synthetic vaccines for mutating viruses. The Company's enabling T-cell vaccine platform enables it to target highly conserved parts of the virus ("antigens") and direct an T-cell immune response to those cells in the body infected with one of these difficult viruses. The fluoropeptide vaccine technology then delivers these antigens into the body and promotes robust T-cell immunity without requiring potentially toxic adjuvants which are normally used with vaccines to boost the responses achieved. The company was founded in late 2003 and is located at the London BioScience Innovation Centre, based in London. In June 2007 the company raised its first major venture capital funding from a syndicate of investors including the Novartis Venture Fund, HealthCap, Truffle Capital & the London Technology Fund. Alongside this investment, the London Development Agency has awarded ITS an Exceptional Development Grant.

Sopherion Therapeutics, LLC is a privately held biopharmaceutical company headquartered in Princeton, New Jersey with offices in Cheshire, Connecticut, Estero, Florida and an operating subsidiary, Sopherion Therapeutics Canada, in Toronto, Canada. Sopherion Therapeutics LLC is a specialty biopharmaceutical company with an exclusive licensing agreement with Zeneus Pharma Ltd., now Cephalon, Inc., for the commercialization of Myocet™ (a liposome-encapsulated doxorubicin-citrate complex) in the United States and Canada. Sopherion’s current business focus is the execution of a Phase III, global, randomized, registration trial for first line therapy of invasive, metastatic breast cancer and the development and commercialization of Sopherion’s lead agent, Myocet™. Myocet is being investigated in an FDA agreed upon registration trial in combination with two other drugs, Herceptin® (Trastuzumab) and Taxol (Paclitaxel) vs. Herceptin® and Taxol alone, the current standard of care for first line HER-2-overexpressing metastatic breast cancer. Myocet™, a liposome-encapsulated doxorubicin with reduced cardiotoxicity, is a nanotechnology product that localizes into tumor vasculature and in contrast to parental doxorubicin avoids homing to the heart. This 363 patient global trial in twelve countries has as of 03/06/09 been fully recruited. Unblinding is anticipated by the summer of 2010 with NDA submission for full approval following within 6 months. Myocet® is already a registered drug in Canada, where Sopherion has commercial rights and in Europe where Cephalon has commercial rights for use in first line metastatic breast cancer in combination with cyclophosphamide.; Their Phase III trial is based on a Phase II trial, supported by Roche, which gave a 96% response rate and two and a half year median progression free survival for patients with metastatic breast cancer.

Hybrigenics Pharma is a bio-pharmaceutical company with a focus on research and development of new targets and therapies against cancer.Hybrigenics Pharma has stopped the development of inecalcitol, a vitamin D receptor agonist.Hybrigenics Pharma's research program investigates the action of enzymes called Deubiquitinating Enzymes (DUBs) in the recycling of onco-proteins and the potential activity of proprietary patented DUB inhibitors against various cancer indications.

Modus Therapeutics AB, a clinical-stage drug development company, develops pharmaceutical therapies. It offers sevuparin, a drug to treat people suffering from sickle cell disease. The company was founded in 2011 and is based in Stockholm, Sweden. Modus Therapeutics AB operates as a subsidiary of Dilafor AB.

Cardoz AB manufactures anti-inflammatory pharmaceuticals to combat heart and vascular disorders. The company was founded in 2006 and is based in Stockholm, Sweden.

SpineVision is a spinal technology company focused on the development and marketing of implants and instrumentation for spinal treatment. The company offers spinal systems addressing a wide range of spinal pathologies including degenerative disc disease, deformity, cervical disorders, trauma and tumors. These products have been developed in collaboration with leading neurological and orthopedic surgeons which has resulted in over 20 patents. SpineVision was founded in 1999 and is headquartered in Antony in France, with subsidiaries in Belgium, Italy, the United Kingdom, and the United States.

Rainier Therapeutics, Inc., a biotechnology company, develops a targeted biologic for the potential treatment of early stage and metastatic bladder cancer. It offers Vofatamab (B-701), a human monoclonal antibody that targets and specifically blocks the activity of FGFR3 (fibroblast growth factor receptor 3) that is used for the treatment for metastatic bladder cancer. Rainier Therapeutics, Inc. was formerly known as BioClin Therapeutics, Inc. and changed its name to Rainier Therapeutics, Inc. in November 2018. The company was founded in 2010 and is based in San Leandro, California.

Aprea AB is a Swedish biotech company focusing on the discovery and development of novel anticancer compounds reactivating the tumor suppressor protein p53. The Company's lead program, APR-246, is a first-in-class small molecule drug candidate in clinical development. Aprea's main shareholder is KDev Investments AB, an investment vehicle owned by Karolinska Development AB (Nasdaq Stockholm: KDEV) and Rosetta Capital Ltd. Other shareholders include Östersjöstiftelsen, Praktikerinvest, and KCIF Co-Investment Fund KB.

ChemoCentryx focuses on discovery, development and commercialization of orally-administered small molecule therapeutics that target chemokine receptors and related chemo-attractant receptors. Their small molecule product candidates is designed to target a specific chemokine or chemo-attractant receptor, thereby blocking the inappropriate immune system cascade underlying a given disease.

CARISMA Therapeutics Inc., a biotechnology company, develops CAR macrophages, an approach to immunotherapy. CARISMA Therapeutics Inc. was formerly known as CARMA Therapeutics Inc. and changed its name to CARISMA Therapeutics Inc. in June 2018. The company was incorporated in 2016 and is headquartered in Philadelphia, Pennsylvania.

LTB4 is developing a naturally occurring molecule stimulating the innate immunity system to target diseases such as infections and cancer.

Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its lead product candidate is FPI-1434 that is in Phase 1 clinical trials as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company is also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it is progressing its earlier-stage product candidate, FPI-1966 into clinical development for the treatment of head and neck, and bladder cancers expressing fibroblast growth factor receptor. The company was founded in 2014 and is headquartered in Hamilton, Canada.

Dynavax Technologies Corporation is a clinical-stage biopharmaceutical company committed to discovering and developing novel products to prevent and treat infectious diseases.

OxThera AB manufactures products for the treatment of primary and secondary hyperoxaluria with bacteria and enzymes. It offers Oxabact, an orally delivered composition of live bacteria to promote the removal of endogenously produced oxalate for the treatment of primary hyperoxaluria and Oxazyme, a non-systemic orally delivered drug composed of recombinant oxalate decarboxylase for the treatment of dietary hyperoxaluria and prevention of kidney stones. The company was founded in 2005 and is based in Stockholm, Sweden with an additional location in Knoxville, Tennessee.

CARISMA Therapeutics Inc., a biotechnology company, develops CAR macrophages, an approach to immunotherapy. CARISMA Therapeutics Inc. was formerly known as CARMA Therapeutics Inc. and changed its name to CARISMA Therapeutics Inc. in June 2018. The company was incorporated in 2016 and is headquartered in Philadelphia, Pennsylvania.

Nexstim is a medical device company that specializes in image-guided transcranial magnetic stimulation. The company is committed to improving the quality of life of patients with significant unmet clinical needs. It has developed a SmartFocus TMS technology designed for the treatment of the major depressive disorder. The company was founded in 2000 and is headquartered in Helsinki, Southern Finland.

CARISMA Therapeutics Inc., a biotechnology company, develops CAR macrophages, an approach to immunotherapy. CARISMA Therapeutics Inc. was formerly known as CARMA Therapeutics Inc. and changed its name to CARISMA Therapeutics Inc. in June 2018. The company was incorporated in 2016 and is headquartered in Philadelphia, Pennsylvania.

Pharmion is a global biotech company that is dedicated to the hematology and oncology communities. We work in partnership with a network of scientific and clinical advisors to identify and develop products for global hematology and oncology markets. To expand each product's potential, we have established our own regulatory, development and sales and marketing organizations in the United States, Europe, and Australia, and we have developed a third-party distributor network to serve the hematology and oncology markets in 20 additional countries throughout the Middle East, Asia, and Latin America. The global capabilities within our sales, marketing and distribution organization distinguishes us from other companies of a similar size. With our international network we can reach physicians and their patients in more than 30 countries. With proven development and regulatory professionals and an experienced global commercialization team, we concentrate our resources on licensing, developing, and commercializing therapeutic products for the treatment of hematology and oncology patients. Through these efforts, we seek to provide greater therapeutic options to hematologists and oncologists with the ultimate goal of extending survival and improving patients’ quality of life.

PTC Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of orally administered and small-molecule drugs. It offers Ataluren, an orally administered small-molecule investigational new drug for the treatment of cystic fibrosis and duchenne muscular dystrophy caused by nonsense mutations. The company also provides PTC299, an anti-angiogenesis drug for the treatment of metastatic breast cancer, multiple tumors, and neurofibromatosis. Its products are used for the treatment of genetic disorders, oncology, and infectious diseases. PTC Therapeutics, Inc. was founded in 1998 and is based in South Plainfield, New Jersey.

PTC Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of orally administered and small-molecule drugs. It offers Ataluren, an orally administered small-molecule investigational new drug for the treatment of cystic fibrosis and duchenne muscular dystrophy caused by nonsense mutations. The company also provides PTC299, an anti-angiogenesis drug for the treatment of metastatic breast cancer, multiple tumors, and neurofibromatosis. Its products are used for the treatment of genetic disorders, oncology, and infectious diseases. PTC Therapeutics, Inc. was founded in 1998 and is based in South Plainfield, New Jersey.

FivePrime is dis­cov­er­ing and devel­op­ing novel ther­a­peu­tic pro­teins and anti­bod­ies by sys­tem­at­i­cally screen­ing all rel­e­vant pro­teins in the human body to find the best pro­tein for treat­ment of a given clin­i­cal indi­ca­tion. FivePrime’s Pro­Screen Engine enables the rapid pro­duc­tion and screen­ing of all ther­a­peu­ti­cally rel­e­vant pro­teins in medically-​​focused assays at the high­est qual­ity stan­dards in the indus­try. This pow­er­ful approach is the polar oppo­site of the industry’s tra­di­tional “one pro­tein at a time”. The Pro­Screen Engine com­prises the defin­i­tive pro­tein col­lec­tion and screen­ing process for bio­log­ics dis­cov­ery and is unprece­dented in its effi­ciency, qual­ity and scale. In addi­tion to DBL Investors, investors include Domain Asso­ciates, Ver­sant Ven­tures, Kleiner Perkins Cau­field and Byers, Texas Pacific Group, Health­Cap and Advanced Tech­nol­ogy Ventures.

Nucleonics is a biotechnology company focused on RNA interference-based therapeutics.

CARISMA Therapeutics Inc., a biotechnology company, develops CAR macrophages, an approach to immunotherapy. CARISMA Therapeutics Inc. was formerly known as CARMA Therapeutics Inc. and changed its name to CARISMA Therapeutics Inc. in June 2018. The company was incorporated in 2016 and is headquartered in Philadelphia, Pennsylvania.

Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its lead product candidate is FPI-1434 that is in Phase 1 clinical trials as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company is also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it is progressing its earlier-stage product candidate, FPI-1966 into clinical development for the treatment of head and neck, and bladder cancers expressing fibroblast growth factor receptor. The company was founded in 2014 and is headquartered in Hamilton, Canada.

Ultragenyx Pharmaceutical develops therapeutics for rare diseases, sometimes referred to as Orphan products. Ultragenyx is a efficient and effective development strategies are essential for success in the rare disease space, in which information may be incomplete or ambiguous, and few development precedents exist. The management team's experience in selecting and developing products with clear mechanisms of action for untreated rare diseases will help Ultragenyx create life-changing therapeutics by leveraging existing yet undeveloped science for these little-known indications.

Strongbridge Biopharma’s primary focus has been to build its franchise around rare endocrine disorders, which includes product candidates for the treatment of endogenous Cushing’s syndrome and acromegaly, two rare diseases with a high unmet need for innovative treatment options. Given the well-identified and concentrated prescriber base addressing its target markets, the Company intends to use a small, focused sales force to market its products, if approved, in the United States, European Union and other key global markets. The Company intends to identify and in-license or acquire products or product candidates that would be complementary to its existing rare endocrine franchise or that would form the basis for new rare disease franchises.

Arpida AG is a biopharmaceutical company that focused on the discovery and development of novel products for the treatment of bacterial infections.

Resistentia Pharmaceuticals, a biopharmaceutical company, develops immunotherapeutic products for allergic asthma and inflammatory disorders. It provides Immunoglobulin E for allergic reactions, including asthma, rhinitis, and dermatitis; and C5a for the treatment of inflammatory conditions, such as rheumatoid arthritis, asthma, and multiple sclerosis. Resistentia Pharmaceuticals AB was founded in 1998 and is based in Uppsala, Sweden.

Renovo is a biopharmaceutical product company and is a leader in the discovery and development of drugs to reduce scarring, improve wound healing and enhance tissue regeneration. We aim to be first to market with a scar reduction pharmaceutical drug in the US and Europe to capitalise on this huge, unmet market need. Our pipeline includes one drug in phase 3 clinical development, two drugs in phase 2 clinical development and numerous pre-clinical candidates.

Ferrokin Biosciences Inc. develops and markets medical devices. The company offers iron chelator for the treatment of iron-overload in patients with transfusion-dependent hereditary and acquired refractory anemias. The company is based in San Carlos, California.

Glionova AB, a development stage biopharmaceutical company, is engaged in the development of therapies for difficult-to-treat cancers. The company develops GLN-1001, an orally bioavailable small molecule that induces selective cell death in glioblastoma cells without causing harm to normal brain tissue. Its GLN-1001 is used to treat patients suffering from glioblastoma (a common and aggressive primary brain tumor). The company also focuses on market its product through strategic partnerships with global oncology focused pharmaceutical companies. Glionova AB was founded in 2014 and is based in Stockholm, Sweden.

CoreValve is a private company founded in 2001 by Jacques Seguin, M.D., Ph.D., a cardiac surgeon. The vision of the Company was to develop a technology that permits the replacement of failing aortic heart valves without surgical access. Developing the concept of a catheter-based aortic valve replacement procedure, the Company has rapidly advanced this technology from vision to reality. Today, more than 200 patients have experienced successful aortic valve replacement with the CoreValve ReValving™ procedure. CoreValve’s objective is to be the technological, clinical, and market leader in percutaneous heart valve replacement therapies. Current efforts are focused on percutaneous aortic valve replacement, but future efforts will relate to other minimally invasive structural heart disease treatments. CoreValve’s headquarters’ are in Irvine, California, an area renowned for the development of innovative heart valve technologies.

Tengion, a clinical-stage biotechnology company, is a leader in developing neo-organs and neo-tissues, currently derived from a patient's own (autologous) cells. The Company has completed two Phase 2 human clinical trial in the United States with its Tengion Neo-Bladder Augment for children with neurogenic bladder due to spina bifida and in adults with neurogenic bladder due to spinal cord injury. A successful academic human clinical experience with a urinary Neo-Bladder Augment was reported in The Lancet in April 2006 by investigators from the Children's Hospital Boston. Tengion has an effective investigational new drug application (IND) for its Neo-Urinary Conduit and expects to begin a Phase 1 clinical trial in the first half of 2010 in bladder cancer patients requiring bladder removal.

Cytos is a public biopharmaceutical company focused on the development of targeted immunotherapies with a VLP B-cell vaccines platform and ongoing preclinical development programs based on the platform.

Doctrin AB operates a healthcare platform for healthcare providers who offer patients digital healthcare services. The platform is a cloud based B2B system for healthcare providers, helping the customers digitalise their patient visits. The company has a technology that replicates how doctors interview their patients. The platform is used for information gathering, decision support, and documentation services. The company was founded in 2016 and is based in Stockholm, Sweden.

CoreValve is a private company founded in 2001 by Jacques Seguin, M.D., Ph.D., a cardiac surgeon. The vision of the Company was to develop a technology that permits the replacement of failing aortic heart valves without surgical access. Developing the concept of a catheter-based aortic valve replacement procedure, the Company has rapidly advanced this technology from vision to reality. Today, more than 200 patients have experienced successful aortic valve replacement with the CoreValve ReValving™ procedure. CoreValve’s objective is to be the technological, clinical, and market leader in percutaneous heart valve replacement therapies. Current efforts are focused on percutaneous aortic valve replacement, but future efforts will relate to other minimally invasive structural heart disease treatments. CoreValve’s headquarters’ are in Irvine, California, an area renowned for the development of innovative heart valve technologies.

Actelion Ltd, a biopharmaceutical company, discovers, develops, and commercializes low molecular weight drugs for unmet medical needs. It sells Tracleer, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension (PAH); Opsumit, an orally available endothelin receptor antagonist; and Ventavis, an inhaled formulation of iloprost, a synthetic compound structurally similar to prostacyclin. The company also provides Veletri, an intravenous prostacyclin for the treatment of PAH to enhance exercise capacity; Zavesca, an oral capsule for the treatment of patients with mild to moderate type 1 Gaucher disease for whom enzyme replacement therapy is not a therapeutic option; Valchlor, a topical formulation of mechlorethamine for the treatment of stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma in patients; and Uptravi, an oral selective IP receptor agonist targeting the prostacyclin pathway in PAH. Actelion Ltd markets its products in Switzerland, the United States, Europe, Japan, and internationally. The company was founded in 1997 and is headquartered in Allschwil, Switzerland. Actelion Ltd operates as a subsidiary of Johnson & Johnson.

Pulmonx Corporation, based in Redwood City, Calif., is focused on developing and marketing minimally-invasive medical devices and technologies for the diagnosis and treatment of pulmonary disorders. The company is currently engaged in the design, development and manufacture of products that will improve the effectiveness and benefits of endoscopic lung volume reduction (ELVR) for patients with severe emphysema. The company’s Zephyr® Endobronchial Valve (EBV) therapy* involves placing small one-way valves in the lung to prevent air from entering the most diseased regions while allowing fluids and trapped air to escape. The goal is to reduce the volume of the diseased portions of the lung, allowing increased ventilation to healthier areas of the lung. The company has CE mark for the Zephyr Endobronchial Valves and has submitted a CE mark application for the Chartis System. The company has 510(k) marketing clearance for the Chartis System in the United States.

Tengion, a clinical-stage biotechnology company, is a leader in developing neo-organs and neo-tissues, currently derived from a patient's own (autologous) cells. The Company has completed two Phase 2 human clinical trial in the United States with its Tengion Neo-Bladder Augment for children with neurogenic bladder due to spina bifida and in adults with neurogenic bladder due to spinal cord injury. A successful academic human clinical experience with a urinary Neo-Bladder Augment was reported in The Lancet in April 2006 by investigators from the Children's Hospital Boston. Tengion has an effective investigational new drug application (IND) for its Neo-Urinary Conduit and expects to begin a Phase 1 clinical trial in the first half of 2010 in bladder cancer patients requiring bladder removal.